ARTEMIS MED SERVICE LTD
Latest filings
Next results: Fri, 30 Oct · Financial Results- Artemis Medicare schedules Q2 and H1 FY27 earnings call · Board & Shareholder Meetings
- Board to approve September 2026 quarterly and half-year results · Results
- Reg 74(5) Compliance Certificate for Quarter Ended Sep 30 2026 · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Runs a chain of multi-specialty hospitals anchored by a flagship facility in Gurugram, with a 300-bed facility in Raipur commenced in July 2026 and a 650-bed South Delhi project (VIMHANS) targeted for FY29, aiming for 2,000+ beds across the network by 2029. In FY26, consolidated revenue was ₹1,081 crores (+15.4% YoY) with EBITDA margin of 20.2% and PAT of ₹104 crores (+26.2%). The Gurugram flagship posted an ARPOB of ₹84,571 and 64.6% occupancy in Q4 FY26, with management targeting 70%+ occupancy to unlock an additional 100 beds under a Platinum Green Building certification that requires no incremental land cost. Roughly 30% of revenue comes from international patients, whose ARPOB is around 1.3x the domestic figure, with management guiding to a 15% pricing hike in FY27 for both segments. The cost stack is dominated by other operating expenses at 43.8% of revenue, followed by materials (consumables, implants, pharmacy) at 23.5% and employee costs at 15.4%. New projects under ramp-up are expected to weigh on FY27 margins, with Raipur alone projected to book a loss of ₹18–20 crore before reaching breakeven at 18 months.
Scorecard
Measured from the filed financials, judged against its Hospital peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from ARTEMIS MED SERVICE LTD's filed financials and exchange disclosures
What does ARTEMIS MED SERVICE LTD do?
ARTEMIS MED SERVICE LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol ARTEMISMED.
Is ARTEMIS MED SERVICE LTD profitable?
Yes. Over the trailing twelve months ARTEMIS MED SERVICE LTD reported a net profit of ₹114 Cr on revenue of ₹1,114 Cr.
Does ARTEMIS MED SERVICE LTD pay a dividend?
Yes. The dividend yield is 0.13% at the current price. It paid out 6% of its profit as dividend in FY26.
Is ARTEMIS MED SERVICE LTD debt-free?
No. It reported borrowings of ₹227 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹193 Cr after cash. Debt stands at 0.24× equity. That is higher than 52% of its 24 Hospital peers.
Is ARTEMIS MED SERVICE LTD expensive compared with its peers?
On trailing P/E, ARTEMIS MED SERVICE LTD ranks 15 of 30 in Hospital — cheaper than 52% of them, against an industry median of 42.0×. This is a position, not a valuation judgement.
How much does the ARTEMIS MED SERVICE LTD share price move in a day?
On a typical session ARTEMIS MED SERVICE LTD moves 1.33% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
When are ARTEMIS MED SERVICE LTD's next results?
Financial Results on Fri, 30 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track ARTEMIS MED SERVICE LTD's announcements?
Every NSE and BSE filing by ARTEMIS MED SERVICE LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.